158 related articles for article (PubMed ID: 21240332)
1. [Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].
Acuña C
Drugs Today (Barc); 2010 Dec; 46 Suppl F():1-12. PubMed ID: 21240332
[TBL] [Abstract][Full Text] [Related]
2. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
Abel T; Fehér J
Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
[TBL] [Abstract][Full Text] [Related]
3. [Type 2 diabetes: interview with Prof. Stephan Matthaei. Reaching HbA1c target value while preventing hypoglycemia].
Matthaei S
MMW Fortschr Med; 2009 Oct; 151(42):54. PubMed ID: 19938786
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
5. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Srivastava S; Saxena GN; Keshwani P; Gupta R
J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
Seck TL; Engel SS; Williams-Herman DE; Sisk CM; Golm GT; Wang H; Kaufman KD; Goldstein BJ
Diabetes Res Clin Pract; 2011 Jul; 93(1):e15-7. PubMed ID: 21477878
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
[TBL] [Abstract][Full Text] [Related]
8. [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].
Perusicová J
Vnitr Lek; 2007 Oct; 53(10):1109-13. PubMed ID: 18072437
[TBL] [Abstract][Full Text] [Related]
9. Sitagliptin for Type 2 diabetes: a 2015 update.
Lee M; Rhee MK
Expert Rev Cardiovasc Ther; 2015 Jun; 13(6):597-610. PubMed ID: 26000559
[TBL] [Abstract][Full Text] [Related]
10. Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.
Mori Y; Taniguchi Y; Matsuura K; Sezaki K; Yokoyama J; Utsunomiya K
Diabetes Technol Ther; 2011 Jul; 13(7):699-703. PubMed ID: 21504334
[TBL] [Abstract][Full Text] [Related]
11. Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies.
Neumiller JJ; Odegard PS; White JR; Setter SM; Campbell RK
Diabetes Educ; 2008; 34(2):183-200. PubMed ID: 18375772
[TBL] [Abstract][Full Text] [Related]
12. [Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)].
Rabasseda X
Drugs Today (Barc); 2011 Nov; 47 Suppl D():1-8. PubMed ID: 22439134
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin: a review.
Subbarayan S; Kipnes M
Expert Opin Pharmacother; 2011 Jul; 12(10):1613-22. PubMed ID: 21651449
[TBL] [Abstract][Full Text] [Related]
14. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Choy M; Lam S
Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
[TBL] [Abstract][Full Text] [Related]
15. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
[TBL] [Abstract][Full Text] [Related]
16. Where is the evidence based on hard endpoints for the safety and effectiveness of sitagliptin in type 2 diabetes?
de Oliveira JM
BMJ; 2013 Jun; 346():f3568. PubMed ID: 23737277
[No Abstract] [Full Text] [Related]
17. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
18. [Sitagliptin].
Taéron C
Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
[No Abstract] [Full Text] [Related]
19. [Combination antidiabetic therapy. Better control of blood glucose values].
Bischoff A
MMW Fortschr Med; 2009 Oct; 151(42):55. PubMed ID: 19938787
[No Abstract] [Full Text] [Related]
20. Sitagliptin: a viewpoint by Mark S. Kipnes.
Kipnes MS
Drugs; 2007; 67(4):598-9. PubMed ID: 17352517
[No Abstract] [Full Text] [Related]
[Next] [New Search]
